Nuvalent closes in on FDA filing for lung cancer drug with topline Phase 1/2 data

Ayisha Sharma

News Reporter

Nuvalent has shared positive data for its ROS1 inhibitor from a “pivotal” mid-stage lung cancer study, and plans to start a rolling NDA submission next …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Nuvalent closes in on FDA filing for lung cancer drug with topline Phase 1/2 data

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Exclusive: FDA's Makary sought rejection of KalVista’s drug in an unusual move by commissioner, sources say

RFK Jr. says he did not commit to upholding ACIP roster to secure Cassidy’s backing

Nektar's mid-stage eczema data deliver key win in bid for company turnaround

Revolution inks up to $2B 'flexible' funding deal to advance RAS inhibitor pipeline

ArriVent plots next steps for lung cancer drug; Neuron23's $96.5M raise

Digital Twins in GMP Manufacturing: Shaping the Future of CPV with Aizon

Nu­va­lent clos­es in on FDA fil­ing for lung can­cer drug with topline Phase 1/2 da­ta

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Ex­clu­sive: FDA's Makary sought re­jec­tion of KalVista’s drug in an un­usu­al move by com­mis­sion­er, sources say

RFK Jr. says he did not com­mit to up­hold­ing ACIP ros­ter to se­cure Cas­sidy’s back­ing

Nek­tar's mid-stage eczema da­ta de­liv­er key win in bid for com­pa­ny turn­around

Rev­o­lu­tion inks up to $2B 'flex­i­ble' fund­ing deal to ad­vance RAS in­hibitor pipeline

Ar­riVent plots next steps for lung can­cer drug; Neu­ron23's $96.5M raise

Dig­i­tal Twins in GMP Man­u­fac­tur­ing: Shap­ing the Fu­ture of CPV with Aizon

Nuvalent closes in on FDA filing for lung cancer drug with topline Phase 1/2 data

Exclusive: FDA's Makary sought rejection of KalVista’s drug in an unusual move by commissioner, sources say

RFK Jr. says he did not commit to upholding ACIP roster to secure Cassidy’s backing

Nektar's mid-stage eczema data deliver key win in bid for company turnaround

Revolution inks up to $2B 'flexible' funding deal to advance RAS inhibitor pipeline

ArriVent plots next steps for lung cancer drug; Neuron23's $96.5M raise

Digital Twins in GMP Manufacturing: Shaping the Future of CPV with Aizon